Hormonal, psychological, and alcohol craving changes after m-chlorophenylpiperazine administration in alcoholics

被引:35
作者
BuydensBranchey, L [1 ]
Branchey, M [1 ]
Fergeson, P [1 ]
Hudson, J [1 ]
McKernin, C [1 ]
机构
[1] SUNY HLTH SCI CTR,DEPT PSYCHIAT,BROOKLYN,NY 11203
关键词
m-CPP challenge; alcoholics; prolactin; cortisol; ''high'' feeling;
D O I
10.1097/00000374-199704000-00007
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
To assess the serotonergic function of alcoholics, their neuroendocrine and psychological responsivities to the serotonergic partial agonist meta-chlorophenylpiperazine (m-CPP) was compared with the responsitivity of healthy subjects, The effect of m-CPP on craving for alcohol was also assessed in the alcoholics, Sixteen patients and 14 controls were tested under double-blind, placebo-controlled conditions, m-CPP (0.5 mg/kg of body weight) was given orally, Alcoholics were tested after a period of abstinence of 15 to 39 days. The two groups of subjects did not differ in their cortisol response to m-CPP, but the prolactin response of alcoholics was significantly blunted, Alcoholics reported a significantly more intense ''high'' feeling after m-CPP than the healthy subjects, m-CPP induced also a decreased craving for alcohol, Our data thus provide further evidence for the existence of a serotonergic dysfunction in alcoholics and a modulation of craving for alcohol by serotonergic systems.
引用
收藏
页码:220 / 226
页数:7
相关论文
共 38 条
[1]  
AMIT Z, 1994, RES ADV NEW PSYCHOPH, P189
[2]  
[Anonymous], 1990, USERS GUIDE STRUCTUR
[3]  
BALLENGER JC, 1979, ARCH GEN PSYCHIAT, V36, P224
[4]  
BENKELFAT C, 1991, ARCH GEN PSYCHIAT, V48, P383
[5]  
BUYDENSBRANCHEY L, 1989, ARCH GEN PSYCHIAT, V46, P231
[6]  
BUYDENSBRANCHEY L, IN PRESS BIOL PSYCHI
[7]  
BUYDENSBRANCHEY L, IN PRESS AM J ADDICT
[8]   INVOLVEMENT OF 5-HT2C RECEPTORS IN MEDIATING THE DISCRIMINATIVE STIMULUS PROPERTIES OF M-CHLOROPHENYLPIPERAZINE (MCPP) [J].
CALLAHAN, PM ;
CUNNINGHAM, KA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 257 (1-2) :27-38
[9]  
ENGEL JA, 1992, NOVEL PHARM INTERVEN, P68